GT Biopharma Announces the Sale of Its Fixed Dose Combination Tablet (GTB-004) for Myasthenia Gravis (Chronic Autoimmune Disease) to DAS Therapeutics September 24, 2019
GT Biopharma Announces FDA Notification of Commencement of Enrollment in Human GTB-3550 Trike™ Phase i/ii Clinical Trial September 12, 2019
GT Biopharma GTB-1550 PHASE I-II Results to be Published in Conjunction With 2019 ASCO Meeting May 31 - June 4 in Chicago May 29, 2019
GT Biopharma (GTBP) to Broadcast Update on TriKE Initiatives for HIV and Oncology at University of Minnesota On May 7th; Dr. Jeff Miller And Dr. Timothy Schacker to Host Event April 25, 2019
GT Biopharma (GTBP) Announces the Elimination of HIV Infected Cells Using its Tri-Specific Killer Engagers (TriKEs) in Preclinical Testing at the University of Minnesota April 24, 2019
